Eiger BioPharmaceuticals develops and sells targeted therapies globally for rare and ultra-rare diseases. Its leading product candidate, Lonafarnib, is a small molecule drug in clinical trials to treat hepatitis delta virus infection. The company's other product candidates are Lambda, Lonafarnib, and Avexitide, which are in clinical trials to treat various conditions.